Infl ammation plays a key role in osteoarthritis (OA). Th e overexpression of cyclooxygenase-2 and proinfl ammatory cytokines has been reported to contribute to the development of OA. Since chronic infl ammation is the leading cause of connective tissue remodeling and destruction in OA, an approach that decreases infl am mation may facilitate the development of an eff ective strategy for its treatment and/or prevention. Th e use of some drugs has demonstrated potential in treatment of OA but longterm safety, resistance and toxicity concerns have hindered their long-term acceptance as viable clinical chemopreventive agents. Th e exploration of new agents, particularly dietary, with low toxicity that can target infl ammatory responses should form the basis for chemopreventive strategies that will reduce the destruction of cartilage matrix.
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Green tea polyphenols (GTPs) -a mixture of major polyphenolic constituents found in green tea, including (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate and (-)-epigallocatechin-3 gallate (EGCG) -off er promising new options for the development of more eff ective strategies for the prevention of infl ammationassociated diseases, including OA. Th e recent study by Akhtar and Haqqi in Arthritis Research and Th erapy indicates that EGCG, the major and most active component of GTPs, protects human chondrocytes from IL-1β-induced infl ammatory responses, and suggests the potential of EGCG in OA treatment/prevention [1] .
Multiple studies were conducted in the research laboratory of Dr Haqqi on the eff ect of GTPs in arthritis using in vitro and in vivo animal models [2] [3] [4] . Th ese studies suggest that GTPs given in drinking water of mice prevented collagen-induced arthritis in the mice, and that this eff ect of GTPs was associated with the marked reduction of collagen-induced infl ammatory mediators such as cyclooxygenase-2 and TNFα in arthritic joints of GTP-fed mice [2] . In vitro studies showed that treatment of human chondrocytes derived from OA cartilage with EGCG inhibits IL-1β-induced activity and expression of cyclo oxygenase-2 and inducible nitric oxide synthase, and inhibits the production of nitric oxide and prostaglandin E 2 in chondrocytes. Th e inhibition of IL-1β-induced proinfl ammatory mediators by EGCG in human chondrocytes was associated with its inhibitory eff ects on the activation and nuclear translocation of NF-κB. Th ese data thus provide a mechanistic link in prevention of arthritis responses as well as potential therapeutic value for EGCG/GTPs inhibiting cartilage resorption in arthritic joints [2] [3] [4] .
Th e IL-1 family consists of 11 members including IL-1β, and the IL-1 receptor family consists of nine separate genes [5] . IL-1β, TNFα and IL-6 are among the key cytokines involved in the pathophysiology of OA. A recent meta-analysis study showed a small but signifi cant association between carriers of the C-T-A haplotype of the Ilirn gene (IL-1 receptor antagonist) and decreased Abstract IL-1β is a major cytokine driving the infl ammatory processes leading to the pathophysiology of osteoarthritis and other infl ammatory diseases. Blockade of IL-1β activity using substances such as the naturally occurring IL-1 receptor antagonist or anti-IL-1β monoclonal antibody are currently being used or tested as therapy. However, such treatments are ineff ective in osteoarthritis. In a recent study, epigallocatechin-3-gallate, a green tea polyphenol, was found to be eff ective in reducing IL-1β-induced infl ammatory cytokines, TNFα, IL-6, granulocytemacrophage colony-stimulating factor and several chemokines from human chondrocytes. The use of green tea polyphenols may be benefi cial as a therapeutic addition to biologics that control IL-1β activity by increasing eff ectiveness and/or reducing dosage.
severity of OA [6] . IL-1 receptor agonist exerts anti-IL-1β infl ammatory activity by binding to the IL-1 receptor, the receptor for both IL-1α and IL-1β [5] . Th erapeutic use of an IL-1 receptor agonist, anakinra, to antagonize IL-1 (IL-1α and IL-1β) activity is a US Food and Drug Administration approved therapy for the treatment of rheumatoid arthritis but not for OA due to its limited and short-term eff ectiveness. Maintaining a balance in levels of IL-1β might be important as a treatment approach for OA, and agents such as GTPs could fi ll the gap. In fact, complete deletion of the Il1b gene leads to disease exacerbation in a mouse model of OA, suggesting both a catabolic and an anabolic role for IL-1β [7] .
Akhtar and Haqqi also showed that GTPs reduce IL-1β-induced granulocyte-macrophage colony-stimulating factor production by chondrocytes [1] . Th is might be of signifi cance in light of the recent exciting fi nding that IL-1-induced granulocyte-macrophage colony-stimulating factor is important for the patho genicity of Th 17, a major eff ector cell driving infl amma tion and autoimmunity [8] . In the photocarcino genesis model, UV radiation-induced infl ammation has been implicated in nonmelanoma and melanoma skin cancers. Topical treatment of the mouse skin with EGCG or oral administration of GTPs in drinking water of mice signifi cantly inhibited UVB radiation-induced infl ammatory responses, and this eff ect of GTPs led to prevention of UV radiation-induced infl ammation-associated skin diseases including skin cancers [9, 10] .
Th e physician and the patients want to understand the real targets and mechanism of action of GTPs that lead to the prevention of arthritis/OA. More in vivo studies are defi nitely required to understand the targets of GTPs in general, and of EGCG in particular, in arthritic/OA animal models. Th e use of GTPs may be better than EGCG as GTPs may have synergistic eff ects, are more stable and are easily aff ordable. It may also be useful to test the eff ect of EGCG or GTPs in combination with other phytochemicals that have anti-infl ammatory activities. Additionally, GTPs should be examined in combi nation with already known drugs for rheumatoid arthritis/ OA. Th is combination may enhance the chemoprotective eff ect of these drugs, lowering the dose of already available drugs that would reduce the toxicity of these drugs if used for treatment long term. Th e road to that point will be long but the study by Akhtar and Haqqi is a promising start in the right direction.
